RGD-modified ZIF-8 nanoparticles as a drug carrier for MR imaging and targeted drug delivery in myocardial infarction.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-07-16 DOI:10.1080/17435889.2024.2365623

Yingxu Li, Maisituremu Tuerhan, Bing Li, Shuangling Chen, Yuji Wang, Yuanyuan Zheng

{"title":"RGD-modified ZIF-8 nanoparticles as a drug carrier for MR imaging and targeted drug delivery in myocardial infarction.","authors":"Yingxu Li, Maisituremu Tuerhan, Bing Li, Shuangling Chen, Yuji Wang, Yuanyuan Zheng","doi":"10.1080/17435889.2024.2365623","DOIUrl":null,"url":null,"abstract":"Aim: A multifunctional nanoplatform has been developed to enhance the targeting capability and biosafety of drug/siRNA for better diagnosis and treatment of myocardial infarction (MI).Materials & methods: The nanoplatform's chemical properties, biodistribution, cardiac magnetic resonance imaging (MRI) capabilities, therapeutic effects and biocompatibility were investigated.Results: The nanoplatform exhibited MI-targeting properties and pH-sensitivity, allowing for effective cardiac MRI and delivery of drugs to the infarcted myocardium. The GCD/Qt@ZIF-RGD demonstrated potential as a reliable MRI probe for MI diagnosis. Moreover, the GCD/si-SHP1/Qt@ZIF-RGD effectively suppressed SHP-1 expression, increased pro-angiogenesis gene expression and reduced cell apoptosis in HUVECs exposed to hypoxia/reoxygenation.Conclusion: Our newly developed multifunctional drug delivery system shows promise as a nanoplatform for both the diagnosis and treatment of MI.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11389745/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2365623","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: A multifunctional nanoplatform has been developed to enhance the targeting capability and biosafety of drug/siRNA for better diagnosis and treatment of myocardial infarction (MI).Materials & methods: The nanoplatform's chemical properties, biodistribution, cardiac magnetic resonance imaging (MRI) capabilities, therapeutic effects and biocompatibility were investigated.Results: The nanoplatform exhibited MI-targeting properties and pH-sensitivity, allowing for effective cardiac MRI and delivery of drugs to the infarcted myocardium. The GCD/Qt@ZIF-RGD demonstrated potential as a reliable MRI probe for MI diagnosis. Moreover, the GCD/si-SHP1/Qt@ZIF-RGD effectively suppressed SHP-1 expression, increased pro-angiogenesis gene expression and reduced cell apoptosis in HUVECs exposed to hypoxia/reoxygenation.Conclusion: Our newly developed multifunctional drug delivery system shows promise as a nanoplatform for both the diagnosis and treatment of MI.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将 RGD 修饰的 ZIF-8 纳米粒子作为药物载体，用于心肌梗塞的磁共振成像和靶向给药。

目的：为了更好地诊断和治疗心肌梗死（MI），我们开发了一种多功能纳米平台，以增强药物/siRNA 的靶向能力和生物安全性。材料与方法：研究纳米平台的化学特性、生物分布、心脏磁共振成像（MRI）能力、治疗效果和生物相容性。结果该纳米平台具有心肌梗死靶向特性和 pH 敏感性，可进行有效的心脏磁共振成像并将药物输送到梗死的心肌。GCD/Qt@ZIF-RGD 显示出作为用于心肌梗死诊断的可靠磁共振成像探针的潜力。此外，GCD/si-SHP1/Qt@ZIF-RGD 能有效抑制 SHP-1 的表达，增加促血管生成基因的表达，并减少暴露于缺氧/复氧条件下的 HUVECs 的细胞凋亡。结论我们新开发的多功能给药系统有望成为诊断和治疗心肌梗死的纳米平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量